De Lucca GV - Search Results

1

Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.

De Lucca GV, Liang J, De Lucca I. De Lucca GV, et al. Among authors: de lucca i. J Med Chem. 1999 Jan 14;42(1):135-52. doi: 10.1021/jm9803626. J Med Chem. 1999. PMID: 9888839

2

Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.

De Lucca GV, Liang J, Aldrich PE, Calabrese J, Cordova B, Klabe RM, Rayner MM, Chang CH. De Lucca GV, et al. J Med Chem. 1997 May 23;40(11):1707-9. doi: 10.1021/jm970081i. J Med Chem. 1997. PMID: 9171880

3

Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.

De Lucca GV, Kim UT, Liang J, Cordova B, Klabe RM, Garber S, Bacheler LT, Lam GN, Wright MR, Logue KA, Erickson-Viitanen S, Ko SS, Trainor GL. De Lucca GV, et al. J Med Chem. 1998 Jun 18;41(13):2411-23. doi: 10.1021/jm980103g. J Med Chem. 1998. PMID: 9632373

4

Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.

Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, Jadhav PK, De Lucca GV, Smyser TE, Klabe RM, Bacheler LT, Rayner MM, Seitz SP. Nugiel DA, et al. Among authors: de lucca gv. J Med Chem. 1996 May 24;39(11):2156-69. doi: 10.1021/jm960083n. J Med Chem. 1996. PMID: 8667359

5

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Hodge CN, et al. Lam PY, et al. J Med Chem. 1996 Aug 30;39(18):3514-25. doi: 10.1021/jm9602571. J Med Chem. 1996. PMID: 8784449

6

Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.

De Lucca GV, Kim UT, Johnson C, Vargo BJ, Welch PK, Covington M, Davies P, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS. De Lucca GV, et al. J Med Chem. 2002 Aug 15;45(17):3794-804. doi: 10.1021/jm0201767. J Med Chem. 2002. PMID: 12166951

7

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

De Lucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB 3rd, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welch PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden DM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS. De Lucca GV, et al. J Med Chem. 2005 Mar 24;48(6):2194-211. doi: 10.1021/jm049530m. J Med Chem. 2005. PMID: 15771462

8

Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.

Brown GD, Shi Q, Delucca GV, Batt DG, Galella MA, Cvijic ME, Liu RQ, Qiu F, Zhao Q, Barrish JC, Carter PH. Brown GD, et al. Bioorg Med Chem Lett. 2016 Jan 15;26(2):662-666. doi: 10.1016/j.bmcl.2015.11.051. Epub 2015 Nov 17. Bioorg Med Chem Lett. 2016. PMID: 26631321

9

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Gavai AV, Norris D, Delucca G, Tortolani D, Tokarski JS, Dodd D, O'Malley D, Zhao Y, Quesnelle C, Gill P, Vaccaro W, Huynh T, Ahuja V, Han WC, Mussari C, Harikrishnan L, Kamau M, Poss M, Sheriff S, Yan C, Marsilio F, Menard K, Wen ML, Rampulla R, Wu DR, Li J, Zhang H, Li P, Sun D, Yip H, Traeger SC, Zhang Y, Mathur A, Zhang H, Huang C, Yang Z, Ranasinghe A, Everlof G, Raghavan N, Tye CK, Wee S, Hunt JT, Vite G, Westhouse R, Lee FY. Gavai AV, et al. J Med Chem. 2021 Oct 14;64(19):14247-14265. doi: 10.1021/acs.jmedchem.1c00625. Epub 2021 Sep 20. J Med Chem. 2021. PMID: 34543572

10

Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV. Shi Q, et al. Among authors: de lucca gv. Bioorg Med Chem Lett. 2014 May 1;24(9):2206-11. doi: 10.1016/j.bmcl.2014.02.075. Epub 2014 Mar 13. Bioorg Med Chem Lett. 2014. PMID: 24685542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters